Stock LIXT LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.26 USD +1.24% Intraday chart for Lixte Biotechnology Holdings, Inc. -5.92% +38.72%
Apr. 23 Lixte Biotechnology Files Up to $50 Million Mixed Shelf MT
Mar. 27 Sector Update: Health Care Stocks Advance Late Afternoon MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 61.46 45.52 39.23 16.36 8.473 5.286
Enterprise Value (EV) 1 57.18 42.93 34.16 11.53 3.12 1.082
P/E ratio -25.6 x -18.7 x -10.9 x -2.38 x -1.28 x -0.88 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - - - - -
EV / FCF -80.3 x -54.2 x -38 x -7.08 x -1.39 x -0.45 x
FCF Yield -1.24% -1.85% -2.63% -14.1% -72.1% -222%
Price to Book 99.7 x -42.7 x 26 x 12.7 x 5.09 x 10.7 x
Nbr of stocks (in thousands) 1,101 1,117 1,237 1,375 1,665 2,249
Reference price 2 55.83 40.74 31.70 11.90 5.090 2.350
Announcement Date 3/25/19 3/25/20 3/26/21 3/21/22 3/29/23 3/19/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - - - - - -
EBIT 1 -2.138 -2.49 -3.266 -6.72 -6.311 -5.09
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -2.133 -2.44 -3.265 -6.728 -6.313 -5.087
Net income 1 -2.133 -2.44 -3.265 -6.728 -6.313 -5.087
Net margin - - - - - -
EPS 2 -2.177 -2.184 -2.895 -4.994 -3.990 -2.660
Free Cash Flow 1 -0.7119 -0.7924 -0.8999 -1.63 -2.249 -2.398
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/25/19 3/25/20 3/26/21 3/21/22 3/29/23 3/19/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 4.27 2.6 5.07 4.82 5.35 4.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -0.71 -0.79 -0.9 -1.63 -2.25 -2.4
ROE (net income / shareholders' equity) -83.3% -74.4% -87.7% -137% -127% -111%
ROA (Net income/ Total Assets) -46.8% -44.4% -51.7% -81.4% -74.1% -64.5%
Assets 1 4.553 5.495 6.317 8.267 8.524 7.891
Book Value Per Share 2 0.5600 -0.9500 1.220 0.9400 1.000 0.2200
Cash Flow per Share 2 3.820 2.330 4.090 3.510 3.220 1.870
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 3/25/19 3/25/20 3/26/21 3/21/22 3/29/23 3/19/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Stock Lixte Biotechnology Holdings, Inc.
+38.72% 7.33M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LIXT Stock
  4. Financials Lixte Biotechnology Holdings, Inc.